Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

BioWorld Insider Podcast: Looking ahead to 2023: CEOs contemplate the new normal

December 5, 2022

Positive results announced from phase 2 trial of oral MS therapeutic

December 1, 2022

Use of Nanoparticles to Combat Neurodegenerative Disease

November 10, 2022

CNM-Au8 Shows Survival Benefit in HEALEY Trial: New Top-line Results

October 4, 2022

HEALEY ALS director says Clene warrants Phase III test despite miss

October 3, 2022

CNM-Au8 Slows Disease Progression in ALS in RESCUE-ALS Phase 2 Trial

October 1, 2022

Early CNM-Au8 Continues to Show Survival Benefits in ALS Patients

September 27, 2022

Clene Energy: Nanocrystal Developer Pursues Remyelination vs. MS, ALS

September 27, 2022

CNM-Au8’s Impact on Survival, Energetic Dysfunction in ALS: Michael Hotchkin

September 23, 2022

CNM-Au8 Displays Evidence of Survival Benefit in Amyotrophic Lateral Sclerosis

September 22, 2022

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved